Proteasomal Ubiquitin Receptor ADRM1 clinical trials
How each study uses Proteasomal Ubiquitin Receptor ADRM1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Proteasomal Ubiquitin Receptor ADRM1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
16 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2019 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 10
Sun Yat-sen University (2) · University of Manitoba (1) · Indication Bioscience LLC (1) · Bateman Horne Center (1) · University of Chicago (1) · Zydus Lifesciences Limited (1) · JW Pharmaceutical (1) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Durvalumab (1) · Cannabidiol (1) · Fospropofol (1) · Propofol (1) · Acetaminophen (1) · Tunlametinib (1) · Fulzerasib (1) · Erlotinib (1)
Studies
Open first, then newest update. How each study uses Proteasomal Ubiquitin Receptor ADRM1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07714447Written as Arm1How we know
- Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07463677Written as Tunlametinib + Cetuximab βHow we know
- Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid AblationNot yet recruitingPhase 4Kaohsiung Medical UniversityNCT06640738Written as arm 1How we know
- A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung CancerNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06620796Written as Arm 1How we know
- Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal CancerActive, not recruitingPhase 1University of ManitobaNCT05667298Written as Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)How we know
- A Study of Atorvo+™ in Healthy Adult ParticipantsCompletedPhase 1Indication Bioscience LLCNCT06615284Written as Atorvo+™ (Arm1)How we know
- Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2CompletedPhase 2Bateman Horne CenterNCT06316843Written as Valacyclovir celecoxib dose 1How we know
- Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep ApneaCompletedNot applicableUniversity of ChicagoNCT00696111Written as Depot Lupron followed by estrogen plus placeboHow we know
- A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral AminosalicylatesCompletedPhase 2Zydus Lifesciences LimitedNCT06398808Written as Arm1How we know
- Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized StudyStatus unknownPhase 2Tata Memorial HospitalNCT02748707Written as Arm1How we know
- Study of of URC102 to Assess the Efficacy and Safety in Gout PatientsCompletedPhase 2JW PharmaceuticalNCT04804111Written as arm 1How we know
- Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DMECompletedPhase 3Novartis PharmaceuticalsNCT02262260Written as Labeled regime armHow we know
- A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable EmulsionCompletedPhase 1Eisai Inc.NCT01308541Written as arm 1How we know
- Dolutegravir + Rilpivirine Switch Study (DORISS)WithdrawnPhase 2/3Nantes University HospitalNCT02069834Written as Arm 1 (intervention)How we know
- Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-beingCompletedPhase 1Mayo ClinicNCT01211912Written as Arm 1 (20 patients)How we know
- Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedPhase 3AmgenNCT00460265Written as ARM 1How we know